Logotype for Valneva SE

Valneva (VLA) investor relations material

Valneva Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Valneva SE
Q3 2025 earnings summary20 Nov, 2025

Executive summary

  • Total revenues for the first nine months of 2025 reached €127.0 million, up 8.9% year-over-year, with product sales of €119.4 million and strong IXIAROⓇ/JESPECTⓇ and IXCHIQⓇ performance despite headwinds.

  • Operating cash burn was significantly reduced to €28.4 million from €76.7 million, supporting a cash position of €143.5 million at period end, including €26.2 million from ATM transactions.

  • Debt refinancing was completed, extending maturity to Q4 2030 and enhancing financial flexibility.

  • Net loss was €65.2 million, compared to a net profit of €24.7 million in 2024, which included a one-time gain from a Priority Review Voucher sale.

  • Key business highlights included responses to disease outbreaks, new contracts, and regulatory progress for multiple vaccines.

Financial highlights

  • Product sales were €119.4 million, up 6.2% year-over-year; IXIAROⓇ/JESPECTⓇ sales rose 12.5% to €74.3 million, and IXCHIQⓇ sales increased 330% to €7.6 million.

  • DUKORALⓇ sales decreased to €21.5 million, impacted by currency and distributor transition in Germany.

  • Gross margin on commercial products (excluding IXCHIQⓇ) improved to 57.2% from 48.6% year-over-year.

  • Operating loss was €53.9 million versus a €34.2 million profit last year, which included a €90.8 million one-time gain from a priority review voucher sale.

  • Adjusted EBITDA was negative €37.7 million, compared to positive €48.6 million last year.

Outlook and guidance

  • Full-year 2025 product sales guidance confirmed at €155–€170 million; total revenues expected at €165–€180 million.

  • R&D expenses projected at €80–€90 million, partially offset by grants and tax credits.

  • Commercial business expected to be cash-flow positive, with lower operational cash burn and focus on maintaining sufficient runway to key milestones.

  • Midterm expectations include continuous product sales growth, strategic R&D investment, and improved gross margin.

  • Sustainable profitability anticipated post-approval and commercialization of the Lyme disease vaccine, potentially from 2027.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Valneva earnings date

Logotype for Valneva SE
Q4 202519 Mar, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Valneva earnings date

Logotype for Valneva SE
Q4 202519 Mar, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Valneva SE is a specialty vaccine company focused on developing and commercializing vaccines for infectious diseases. It targets diseases with significant unmet medical needs through proprietary and partnered programs. The company is headquartered in Saint-Herblain, France, and its shares are listed on the Euronext Paris.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage